Developer docs
API playgroundTry for free, no card

Search company profiles

SpinChip Diagnostics

Full company profile

uuid0003tyy

Namestring
SpinChip Diagnostics
Legal namestring
SpinChip Diagnostics ASA
Websiteurl
spinchip.no
Company typeenum
Private
Founded yearint
2012
Descriptiontext

SpinChip Diagnostics ASA, founded in 2012 in Oslo, Norway, developed a proprietary point-of-care (POC) in vitro diagnostics platform targeted at acute care settings where rapid laboratory-quality results drive time-critical treatment decisions. The platform combines dual axle centrifugal microfluidics with nanotechnology-based assays in single-use cartridges to deliver results from a droplet of blood in approximately ten minutes. The lead commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction, with additional assays in development for sepsis and other cardiovascular biomarkers. Clinical performance was validated in the APACE study, published in the Journal of the American College of Cardiology in 2024, demonstrating diagnostic accuracy comparable to established central laboratory analyzers (Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI) across 3,293 plasma samples from 1,182 patients.

The platform consists of two core products: the SpinChip Analyzer (a desktop instrument integrating mechanics, mechatronics, electronics, optics, a touch display, connectivity features, embedded software, and dual complementary optical readout systems) and disposable microfluidic test cartridges containing both liquid and dried reagents in closed, contamination-free formats. The commercial model is a razor-and-blade hardware-plus-consumables proposition: instrument placement drives recurring revenue per cartridge. The primary customer use case is rapid triage of chest-pain patients in hospital emergency departments, with secondary targets in prehospital care, general practice, and remote settings. Go-to-market was planned as a phased European rollout (Nordics, BeNeLux, DACH) supported by a strategic European distribution partnership and direct hospital clinical collaborations (e.g., Basel University Hospital, Akershus University Hospital). ISO 13485:2016 certification was obtained in September 2023, a cGMP-compliant pilot cartridge production line was operating at 500–750 cartridges per day, and CE mark filing was scheduled for 2025 with commercial launch planned for H1 2026.

SpinChip was acquired by bioMérieux, a global in vitro diagnostics leader, in January 2025 for a Total Enterprise Value of EUR 138 million (NOK 1,624 million), one of the largest MedTech transactions in Norway. Prior to the full acquisition, bioMérieux had invested NOK 115 million in March 2024 as lead investor in a NOK 145 million placement, becoming the second-largest shareholder at 17–20% before completing the take-private. Historical backers included Investinor (anchor investor since 2016), Christen Sveaas (cornerstone investor, NOK 30 million in 2021), SINTEF, and MP Pensjon. SpinChip was pre-revenue at the time of acquisition; under bioMérieux ownership, the platform is being integrated as the foundation of bioMérieux's POC strategy, with planned menu expansion in acute care and global commercial rollout via bioMérieux's existing sales infrastructure.

Short descriptiontext

Oslo-based medtech company SpinChip Diagnostics, acquired by bioMérieux in January 2025, developed a proprietary point-of-care IVD platform using dual axle centrifugal microfluidics and disposable cartridges to deliver lab-quality high-sensitivity cardiac troponin I results within ten minutes from a blood droplet, targeting emergency departments and acute care settings.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, in vitro diagnostics, cardiac troponin testing, microfluidic diagnostic platform, acute care testing
Industry1 code
PRIMARYHLAHAOAC
Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Point-of-Care In Vitro Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Point-of-Care Diagnostic Platform Sales
TypeHardware Sales
Description

Sale of SpinChip Analyzer (desktop instrument) and assay-specific test cartridges. Platform is designed for scalability with ability to perform broad range of tests across therapeutic areas including cardiovascular, inflammatory/sepsis, infectious, and endocrine diseases.

spinchip.no
2Assay/Cartridge Sales
TypeOne Time License
Description

Recurring revenue from sale of disposable test cartridges optimized for different diagnostic tests (cardiac markers like troponin I, sepsis biomarkers, etc.). Cartridges contain integrated liquid and dried reagents for specific assays.

spinchip.no
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SpinChip Diagnostics develops and produces an all-in-one point-of-care in vitro diagnostics platform consisting of the SpinChip Analyzer (a desktop instrument with proprietary dual axle centrifugal microfluidics and dual optical readout systems) and disposable SpinChip Test Cartridges containing integrated liquid and dried reagents. The platform delivers lab-quality diagnostic results in approximately 10 minutes from a droplet of blood at the patient's side, with the lead commercial assay being the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • SpinChip hs-cTnI POC test demonstrated diagnostic accuracy comparable to Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI laboratory assays in APACE study with 3,293 plasma samples from 1,182 patients
+3 more records
Product overview1 text field

SpinChip Diagnostics offers an all-in-one point-of-care in vitro diagnostics platform consisting of two core products: the SpinChip Analyzer (a desktop instrument with dual axle centrifugal microfluidics and dual optical readout systems) and SpinChip Test Cartridges (disposable cartridges with integrated liquid and dried reagents). The platform delivers lab-quality diagnostic results within minutes from a droplet of blood at the point of patient care. The first commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for acute myocardial infarction diagnosis, with additional assays in development for sepsis and other cardiovascular biomarkers.

Product and service3 records
1SpinChip Analyzer
CategoryDiagnostic Instrument / Analyzer
Description

A desktop point-of-care analyzer that processes disposable SpinChip Test Cartridges. It includes mechanics, mechatronics, electronics, optics, a user touch interface, connectivity features, and embedded software. It features a unique dual axle centrifugal system that enables automated cartridge processing, and dual complementary optical readout systems for result generation and communication. Built for hospitals, emergency departments, urgent care units, and other acute care settings that need lab-quality diagnostic results in minutes.

2SpinChip Test Cartridge
CategoryDiagnostic Consumable / Test Cartridge
Description

Disposable microfluidic test cartridge that holds both liquid and dried reagents. It processes samples and reagents according to specific assaying and readout principles using centrifugal force for liquid handling, including reagent dissolution, mixing, splitting, exact metering, dispensing, and flow through filters. Designed for use with the SpinChip Analyzer across multiple assay types (cardiac, sepsis, inflammatory, infectious, endocrine).

3High-Sensitivity Cardiac Troponin I (hs-cTnI) Test
CategoryDiagnostic Assay / Immunoassay
Description

A high-sensitivity immunoassay for early detection of acute myocardial infarction (heart attack), run on the SpinChip Analyzer and Cartridge platform. Demonstrated diagnostic performance comparable to central laboratory assays (Roche Elecsys hs-cTnT, Abbott Architect hs-cTnI) in the APACE clinical study published in JACC, with results delivered in approximately 10 minutes from a droplet of blood. Targeted at hospital emergency departments, urgent care units, and acute care settings.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

QuidelOrtho's Triage MeterPro and TriageTrue platforms deliver POC cardiac biomarkers (Troponin I, BNP, D-dimer) in emergency and acute care settings. Directly comparable to SpinChip as a same-vertical cardiac POC immunoassay platform with razor/blade cartridge economics.

2Abbott Point of Care (i-STAT)
TypeDirect peer
Description

Abbott's i-STAT system is one of the most widely deployed POC platforms globally, with a hs-cTnI cartridge directly competing against SpinChip's troponin assay in emergency departments. Same target customer (hospital EDs), same assay category, same business model of analyzer + disposable cartridge.

TypeDirect peer
Description

Siemens' Atellica VTLI is a POC immunoassay system with a cardiac menu including high-sensitivity troponin I, designed for emergency and acute-care use. Direct competitor to SpinChip on assay menu, performance claims, and customer base.

TypeDirect peer
Description

Radiometer's AQT90 FLEX is a POC immunoassay analyzer used in emergency departments for cardiac markers including troponin. Direct peer in target customer (hospital EDs/acute care), assay category, and POC platform economics; Radiometer is a Danaher-owned incumbent.

TypeDirect peer
Description

Response Biomedical's RAMP platform is a POC cardiovascular testing system with troponin I assays marketed to emergency departments and acute care. Directly comparable niche player targeting the same cardiac POC opportunity as SpinChip.

TypeDirect peer
Description

Trinity Biotech offers POC cardiac biomarker tests including troponin I on its Meritas and related platforms. A specialty IVD peer in the same cardiac POC segment as SpinChip, targeting hospital labs and acute care settings.

7Boditech Med
TypeEmerging player
Description

South Korea-based Boditech Med develops POC immunoassay platforms (ichroma series) with cardiac panels including troponin I. Comparable as an emerging POC player in cardiac diagnostics with a similar cartridge-based architecture, though stronger in Asian markets than Europe.

TypeBroad incumbent
Description

bioMérieux's VIDAS franchise is a broad immunoassay menu including cardiac biomarkers, and bioMérieux is now SpinChip's parent company. A broader IVD incumbent whose VIDAS platform overlaps SpinChip's roadmap and whose global distribution is now the primary commercialization channel for SpinChip.

TypeBroad incumbent
Description

Roche's cobas Liat is a rapid POC molecular PCR system used in urgent care and EDs; Roche Elecsys hs-cTnT is the central-lab benchmark SpinChip matched in the APACE study. Broader IVD incumbent whose lab assay is the direct competitor SpinChip displaces at the POC.

TypeEmerging player
Description

EKF Diagnostics' QuikRead and related POC products include CRP and other acute-care biomarkers; smaller-scale POC peer targeting similar primary care and acute care customers. Comparable in business model (analyzer + disposable) though with a different assay focus than SpinChip's cardiac-first menu.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpinChip Diagnostics

Point-of-Care In Vitro Diagnosticsspinchip.no

Oslo-based medtech company SpinChip Diagnostics, acquired by bioMérieux in January 2025, developed a proprietary point-of-care IVD platform using dual axle centrifugal microfluidics and disposable cartridges to deliver lab-quality high-sensitivity cardiac troponin I results within ten minutes from a blood droplet, targeting emergency departments and acute care settings.

What SpinChip Diagnostics does

SpinChip Diagnostics ASA, founded in 2012 in Oslo, Norway, developed a proprietary point-of-care (POC) in vitro diagnostics platform targeted at acute care settings where rapid laboratory-quality results drive time-critical treatment decisions. The platform combines dual axle centrifugal microfluidics with nanotechnology-based assays in single-use cartridges to deliver results from a droplet of blood in approximately ten minutes. The lead commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction, with additional assays in development for sepsis and other cardiovascular biomarkers. Clinical performance was validated in the APACE study, published in the Journal of the American College of Cardiology in 2024, demonstrating diagnostic accuracy comparable to established central laboratory analyzers (Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI) across 3,293 plasma samples from 1,182 patients.

The platform consists of two core products: the SpinChip Analyzer (a desktop instrument integrating mechanics, mechatronics, electronics, optics, a touch display, connectivity features, embedded software, and dual complementary optical readout systems) and disposable microfluidic test cartridges containing both liquid and dried reagents in closed, contamination-free formats. The commercial model is a razor-and-blade hardware-plus-consumables proposition: instrument placement drives recurring revenue per cartridge. The primary customer use case is rapid triage of chest-pain patients in hospital emergency departments, with secondary targets in prehospital care, general practice, and remote settings. Go-to-market was planned as a phased European rollout (Nordics, BeNeLux, DACH) supported by a strategic European distribution partnership and direct hospital clinical collaborations (e.g., Basel University Hospital, Akershus University Hospital). ISO 13485:2016 certification was obtained in September 2023, a cGMP-compliant pilot cartridge production line was operating at 500–750 cartridges per day, and CE mark filing was scheduled for 2025 with commercial launch planned for H1 2026.

SpinChip was acquired by bioMérieux, a global in vitro diagnostics leader, in January 2025 for a Total Enterprise Value of EUR 138 million (NOK 1,624 million), one of the largest MedTech transactions in Norway. Prior to the full acquisition, bioMérieux had invested NOK 115 million in March 2024 as lead investor in a NOK 145 million placement, becoming the second-largest shareholder at 17–20% before completing the take-private. Historical backers included Investinor (anchor investor since 2016), Christen Sveaas (cornerstone investor, NOK 30 million in 2021), SINTEF, and MP Pensjon. SpinChip was pre-revenue at the time of acquisition; under bioMérieux ownership, the platform is being integrated as the foundation of bioMérieux's POC strategy, with planned menu expansion in acute care and global commercial rollout via bioMérieux's existing sales infrastructure.

SpinChip Diagnostics firmographics

Firmographics
Name
SpinChip Diagnostics
Legal name
SpinChip Diagnostics ASA
Website
https://spinchip.no
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
Oslo-based medtech company SpinChip Diagnostics, acquired by bioMérieux in January 2025, developed a proprietary point-of-care IVD platform using dual axle centrifugal microfluidics and disposable cartridges to deliver lab-quality high-sensitivity cardiac troponin I results within ten minutes from a blood droplet, targeting emergency departments and acute care settings.
Ownership category
akta.pro rank

SpinChip Diagnostics industry classification

Industry
Product category
Point-of-Care In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAOAC
Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Point-of-care diagnostics
  • In vitro diagnostics
  • Cardiac troponin testing
  • Microfluidic diagnostic platform
  • Acute care testing

Where SpinChip Diagnostics is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

SpinChip Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Point-of-Care Diagnostic Platform Sales: Sale of SpinChip Analyzer (desktop instrument) and assay-specific test cartridges. Platform is designed for scalability with ability to perform broad range of tests across therapeutic areas including cardiovascular, inflammatory/sepsis, infectious, and endocrine diseases.
  2. Assay/Cartridge Sales: Recurring revenue from sale of disposable test cartridges optimized for different diagnostic tests (cardiac markers like troponin I, sepsis biomarkers, etc.). Cartridges contain integrated liquid and dried reagents for specific assays.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

SpinChip Diagnostics product offering

Product offering

Core offering

SpinChip Diagnostics develops and produces an all-in-one point-of-care in vitro diagnostics platform consisting of the SpinChip Analyzer (a desktop instrument with proprietary dual axle centrifugal microfluidics and dual optical readout systems) and disposable SpinChip Test Cartridges containing integrated liquid and dried reagents. The platform delivers lab-quality diagnostic results in approximately 10 minutes from a droplet of blood at the patient's side, with the lead commercial assay being the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction.

Product overview

SpinChip Diagnostics offers an all-in-one point-of-care in vitro diagnostics platform consisting of two core products: the SpinChip Analyzer (a desktop instrument with dual axle centrifugal microfluidics and dual optical readout systems) and SpinChip Test Cartridges (disposable cartridges with integrated liquid and dried reagents). The platform delivers lab-quality diagnostic results within minutes from a droplet of blood at the point of patient care. The first commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for acute myocardial infarction diagnosis, with additional assays in development for sepsis and other cardiovascular biomarkers.

Differentiator

Problem solved

Functional benefit

Products and services

  • SpinChip Analyzer A desktop point-of-care analyzer that processes disposable SpinChip Test Cartridges. It includes mechanics, mechatronics, electronics, optics, a user touch interface, connectivity features, and embedded software. It features a unique dual axle centrifugal system that enables automated cartridge processing, and dual complementary optical readout systems for result generation and communication. Built for hospitals, emergency departments, urgent care units, and other acute care settings that need lab-quality diagnostic results in minutes.
  • SpinChip Test Cartridge Disposable microfluidic test cartridge that holds both liquid and dried reagents. It processes samples and reagents according to specific assaying and readout principles using centrifugal force for liquid handling, including reagent dissolution, mixing, splitting, exact metering, dispensing, and flow through filters. Designed for use with the SpinChip Analyzer across multiple assay types (cardiac, sepsis, inflammatory, infectious, endocrine).
  • High-Sensitivity Cardiac Troponin I (hs-cTnI) Test A high-sensitivity immunoassay for early detection of acute myocardial infarction (heart attack), run on the SpinChip Analyzer and Cartridge platform. Demonstrated diagnostic performance comparable to central laboratory assays (Roche Elecsys hs-cTnT, Abbott Architect hs-cTnI) in the APACE clinical study published in JACC, with results delivered in approximately 10 minutes from a droplet of blood. Targeted at hospital emergency departments, urgent care units, and acute care settings.

Quantifiable outcome

  • SpinChip hs-cTnI POC test demonstrated diagnostic accuracy comparable to Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI laboratory assays in APACE study with 3,293 plasma samples from 1,182 patients
  • +3 more outcomes

Companies that use SpinChip Diagnostics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

SpinChip Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SpinChip Diagnostics partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

SpinChip Diagnostics competitors and assessment

Company assessment

Direct peers

  • QuidelOrtho (Triage): QuidelOrtho's Triage MeterPro and TriageTrue platforms deliver POC cardiac biomarkers (Troponin I, BNP, D-dimer) in emergency and acute care settings. Directly comparable to SpinChip as a same-vertical cardiac POC immunoassay platform with razor/blade cartridge economics.
  • Abbott Point of Care (i-STAT): Abbott's i-STAT system is one of the most widely deployed POC platforms globally, with a hs-cTnI cartridge directly competing against SpinChip's troponin assay in emergency departments. Same target customer (hospital EDs), same assay category, same business model of analyzer + disposable cartridge.
  • Siemens Healthineers (Atellica VTLI): Siemens' Atellica VTLI is a POC immunoassay system with a cardiac menu including high-sensitivity troponin I, designed for emergency and acute-care use. Direct competitor to SpinChip on assay menu, performance claims, and customer base.
  • Radiometer (Danaher) — AQT90 FLEX: Radiometer's AQT90 FLEX is a POC immunoassay analyzer used in emergency departments for cardiac markers including troponin. Direct peer in target customer (hospital EDs/acute care), assay category, and POC platform economics; Radiometer is a Danaher-owned incumbent.
  • Response Biomedical (RAMP): Response Biomedical's RAMP platform is a POC cardiovascular testing system with troponin I assays marketed to emergency departments and acute care. Directly comparable niche player targeting the same cardiac POC opportunity as SpinChip.
  • Trinity Biotech (Meridian branded POC): Trinity Biotech offers POC cardiac biomarker tests including troponin I on its Meritas and related platforms. A specialty IVD peer in the same cardiac POC segment as SpinChip, targeting hospital labs and acute care settings.

Emerging players

  • Boditech Med: South Korea-based Boditech Med develops POC immunoassay platforms (ichroma series) with cardiac panels including troponin I. Comparable as an emerging POC player in cardiac diagnostics with a similar cartridge-based architecture, though stronger in Asian markets than Europe.
  • EKF Diagnostics (QuikRead): EKF Diagnostics' QuikRead and related POC products include CRP and other acute-care biomarkers; smaller-scale POC peer targeting similar primary care and acute care customers. Comparable in business model (analyzer + disposable) though with a different assay focus than SpinChip's cardiac-first menu.

Broad incumbents

  • bioMérieux (VIDAS): bioMérieux's VIDAS franchise is a broad immunoassay menu including cardiac biomarkers, and bioMérieux is now SpinChip's parent company. A broader IVD incumbent whose VIDAS platform overlaps SpinChip's roadmap and whose global distribution is now the primary commercialization channel for SpinChip.
  • Roche Diagnostics (cobas Liat): Roche's cobas Liat is a rapid POC molecular PCR system used in urgent care and EDs; Roche Elecsys hs-cTnT is the central-lab benchmark SpinChip matched in the APACE study. Broader IVD incumbent whose lab assay is the direct competitor SpinChip displaces at the POC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

SpinChip Diagnostics social profiles

Digital presence

SpinChip Diagnostics compliance and trust

Trust signal

Compliance1 record

SpinChip Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpinChip Diagnostics leadership team

Management profile

Number of profiles

Profiles10 records

SpinChip Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpinChip Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpinChip Diagnostics

What does SpinChip Diagnostics do?

SpinChip Diagnostics develops and produces an all-in-one point-of-care in vitro diagnostics platform consisting of the SpinChip Analyzer (a desktop instrument with proprietary dual axle centrifugal microfluidics and dual optical readout systems) and disposable SpinChip Test Cartridges containing integrated liquid and dried reagents. The platform delivers lab-quality diagnostic results in approximately 10 minutes from a droplet of blood at the patient's side, with the lead commercial assay being the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction.

Is SpinChip Diagnostics a public or private company?

SpinChip Diagnostics is a private company. It is classified as corporate owned and is currently acquired.

When was SpinChip Diagnostics founded?

SpinChip Diagnostics was founded in 2012. It employs 51 to 100 people.

Where is SpinChip Diagnostics based?

SpinChip Diagnostics is headquartered in Oslo, Norway, in the Europe region.

How does SpinChip Diagnostics make money?

Two revenue lines are on record. Point-of-Care Diagnostic Platform Sales are the primary driver. The others are assay/Cartridge Sales.

Who are SpinChip Diagnostics's main competitors?

Direct peers on record are QuidelOrtho (Triage), Abbott Point of Care (i-STAT), Siemens Healthineers (Atellica VTLI), Radiometer (Danaher) — AQT90 FLEX, Response Biomedical (RAMP) and Trinity Biotech (Meridian branded POC). Emerging players are Boditech Med and EKF Diagnostics (QuikRead). Broad incumbents are bioMérieux (VIDAS) and Roche Diagnostics (cobas Liat).

Does SpinChip Diagnostics have an API?

No public API is recorded for SpinChip Diagnostics.

What industry is SpinChip Diagnostics in?

SpinChip Diagnostics's product category is Point-of-Care In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAC, Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGlobal Point-of-Care Molecular Diagnostics Market is Expected to Expand at a Healthy Growth Rate of ~10% by 2034 | DelveInsightThe global point-of-care molecular diagnostics market is projected to grow from USD 6.2 billion in 2025 to USD 14.8 billion by 2034, a ~10% CAGR. North America holds the largest share at 46%, with Asia-Pacific expected to see the highest growth. Key drivers include rising infectious disease burden and technological advancements.GlobeNewswireRapid Immunoassay Analyzers Market Report 2026ResearchAndMarkets.com published its Rapid Immunoassay Analyzers Market Report 2026, projecting the market to grow from $1.23 billion in 2025 to $1.36 billion in 2026 (10.8% CAGR) and reach $2.08 billion by 2030 (11.1% CAGR). Key market drivers include rising prevalence of infectious and chronic diseases, demand for point-of-care testing, and technological advancements in portable diagnostic devices. Notable strategic moves include Boditech Med Inc. showcasing its expanded portable diagnostics lineup at MEDICA 2025 and bioMerieux acquiring SpinChip Diagnostics in January 2025 to strengthen its decentralized healthcare offerings.GlobeNewswireRapid Immunoassay Analyzers Market Report 2026The global rapid immunoassay analyzers market is projected to grow from $1.23 billion in 2025 to $1.36 billion in 2026 and reach $2.08 billion by 2030, driven by increasing demand for point-of-care diagnostics, rising chronic and infectious disease prevalence, and advancements in portable diagnostic technologies. In January 2025, bioMerieux acquired SpinChip Diagnostics to strengthen its point-of-care offerings, and in November 2025, Boditech Med Inc. showcased its expanded portable diagnostics lineup at MEDICA 2025. The market is shifting toward portable immunoassay analyzers and multiplex testing, with North America leading in 2025 while Asia-Pacific is expected to see the fastest growth.GlobeNewswireSouth Africa $121.8 Mn IVD Centralized Diagnostics Market Dynamics, Developments, and Forecasts 2025-2026 & 2032Research and Markets published a report on the South Africa in-vitro diagnostics (IVD) centralized diagnostics market, valued at US$ 76.6 million in 2025 and projected to reach US$ 121.8 million by 2032, making it the largest and most mature IVD market in Sub-Saharan Africa. The report identifies immunoassays and clinical chemistry as the largest segments, with Roche, Abbott, Siemens Healthineers, and Beckman Coulter among the leading players across various sub-segments. Recent developments cited include Roche's CE Mark approval for its Elecsys ApoE4 biomarker test (March 2026), Siemens Healthineers' My Green Lab ACT Ecolabel Certification (July 2025), Labcorp's agreement to acquire assets from BioReference Health (March 2025), and bioMerieux's completion of its acquisition of SpinChip Diagnostics (January 2025).openPR.comKey Factors and Emerging Trends Shaping the Immunochemistry Diagnostic Devices and Equipment Market LandscapeThe immunochemistry diagnostic devices and equipment market is projected to reach $6.22 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.9%, driven by technological advancements, rising demand for automated laboratory systems, and expanded applications in personalized medicine. In January 2025, France-based bioMérieux acquired Norway-based SpinChip Diagnostics ASA for approximately $159.87 million to strengthen its point-of-care diagnostics portfolio with SpinChip's high-sensitivity immunoassay platform capable of delivering rapid results from whole blood samples in about 10 minutes. The market is also seeing innovation in multiplex testing platforms, with Navigate BioPharma Services launching new multiplex digital PCR assays in June 2023 designed to quantify CAR-T cells for cancer immunotherapy monitoring.The Mass Spectrometry Web PortalbioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile.bioMérieux agreed to acquire SpinChip Diagnostics, a Norwegian immunoassay startup, for €138m, with cash out of €111m. The acquisition aims to strengthen point-of-care diagnostics, with the first product launch expected in 2026. SpinChip will focus on cardiac markers like high-sensitivity troponin I.GlobeNewswireSpinChip® Secures NOK 130 million (€13.5 Million) in Financing RoundSpinChip Diagnostics completed a NOK 130 million (€13.5 million) private placement, with Carnegie Investment Bank as bookrunner. Proceeds will fund development of its point-of-care diagnostics platform and a manufacturing plant. The company is preparing for clinical trials and CE-marking, with its first offering in acute cardiac.